India, Feb. 18 -- Shares of Solid Biosciences Inc. (SLDB) surged nearly 50% on Tuesday morning after the life sciences company reported positive initial clinical data from next-generation Duchenne Gene therapy candidate SGT-003.
SLDB is currently trading at $6.00, up $1.97 or 48.87%, on a heavy volume of 56 million shares, above average volume of 0.5 million, on the Nasdaq. The stock opened its trading at $6.69 after closing Friday at $4.03. The stock has traded between $2.88 and $15.05 in the past 52-week period.
Solid Biosciences announced positive initial data from the phase 1/2 Inspire Duchenne trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Interim...